Mitochon Pharmaceuticals is a clinically staged biotech that is focused on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Our development programs are primarily focused on neurodegenerative diseases including: Huntington’s Disease, Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, Parkinson and Traumatic Brain Injury (TBI). Despite that these indications may appear different, on-going research suggests in fact a common link that all are rooted in mitochondrial dysfunction associated with overt free radical production, lower ATP production, calcium overload and slow turnover associated with aging.  By correcting mitochondrial physiology, we aim at opening the way for a broad range of disease modifying therapies. Our platform is based upon mitochondrial enhancers that specifically target the mitochondria as an oral once-per-day brain penetrating therapy that wakes up compensatory pathways pro-survival (MOA:  https://www.mitochonpharma.com/mechanism-of-action/).  Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.

Mitochon Pharmaceuticals, Inc.

Org chart

Teams

Offices